Protherics PLC
Total Voting Rights and Share Capital
London, UK; Brentwood, TN; 4 January 2007. In conformity with the Transparency
Directive's transitional provision 6, Protherics PLC ("Protherics"), the
international biopharmaceutical company focused on critical care and cancer, is
required to notify the market of the following:
Protherics' issued share capital consists of 338,976,174 ordinary shares with a
nominal value of 2 pence each, with voting rights. Protherics does not hold any
ordinary shares in Treasury.
Therefore, the total number of voting rights in Protherics is 338,976,174.
The above figure of 338,976,174 shares may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in,
Protherics under the Financial Service Authority's Disclosure and Transparency
Rules.
| Ends |
For further information please contact:
Protherics
Barry Riley, CFO +44 (0) 1928 518 000
Julie Vickers, Company Secretary +44 (0) 1928 518 010
Financial Dynamics - press enquiries
London: Ben Atwell, David Yates +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
Protherics PLC announces Total Voting Rights
| Source: Protherics PLC
Cheshire, UK -- (MARKET WIRE) -- January 4, 2007 --